Navigation Links
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
Date:8/24/2011

ce daily in the oral treprostinil group. Discontinuations due to adverse events were 18 (11%) and 5 (3%) in the treprostinil and placebo groups, respectively. Adverse events associated with discontinuations were typically prostacyclin-related effects including headache, nausea and vomiting.

Preliminary analysis of other secondary efficacy measures, including time to clinical worsening, change in combined 6MWD and Borg Dyspnea Score rating (shortness of breath test) and Dyspnea-Fatigue index, WHO functional class, and PAH signs and symptoms, did not differ significantly between oral treprostinil and placebo (p>0.05).

Further review and analysis of the FREEDOM-C(2) preliminary results are ongoing.  A summary of the preliminary analysis conducted thus far can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm beginning at 5:00 a.m. Eastern Time on August 24, 2011.  Full data from FREEDOM-C(2) will be presented at an upcoming medical meeting and will also be available through the publication of peer-reviewed journal articles.

"While we did not achieve a statistically significant result for this trial, we believe the positive results from our previously-announced FREEDOM-M study support an NDA filing of oral treprostinil in treatment naive patients," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer. "Given that treprostinil is already approved for use in PAH by subcutaneous, intravenous and inhaled routes of administration, we believe the data obtained from all FREEDOM trials support an NDA for oral treprostinil in this indication," added Dr. Jeffs. "We will now focus on completing the NDA for filing by the first half of 2012."

Conference Call

On Wednesday, August 24, 2011 at 9:00 a.m. United Therapeutics will host a one-hour conference call to answer questions related to FREEDOM-C(2).

<
'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat
11. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... registered accounting firm, Ernst & Young LLP ("EY") that it ... in a letter delivered to the Company on September 15, ... 16, 2014.  PDL has issued the following ... received a number of inquiries on the reason for the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
(Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Oncothyreon Announces Proposed Public Offerings 2
... Communications , a provider of enterprise networking components, has ... of communications technology. , ,This funding, part of the ... competitive award process. It will enable the company to ... States Army . , ,The request for funding was ...
... I always like about the annual BIO International Conference ... Young always releases at this event its latest report ... Global Biotechnology Industry 2007. , ,This report is chock ... than Ernst & Young covers the global growth of this ...
... from the Public Company Accounting Oversight Board ... within information systems. There are numerous studies, including our ... area. It is worth making the investment to fix ... savings with your Sarbanes-Oxley compliance program. , ...
Cached Biology Technology:The state of global biotech: An Ernst & Young perspective 2The state of global biotech: An Ernst & Young perspective 3The state of global biotech: An Ernst & Young perspective 4The state of global biotech: An Ernst & Young perspective 5The state of global biotech: An Ernst & Young perspective 6Why IT change management is more important than ever 2Why IT change management is more important than ever 3Why IT change management is more important than ever 4
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
(Date:9/17/2014)... team of Spanish researchers have obtained the first partial ... sixteenth century pig found at the site of the ... this ancient pig is closely related to today,s Iberian ... were crossed with modern Iberian pigs. , The study, ... evolutionary aspects of pig species, and particularly on that ...
(Date:9/17/2014)... After decades of decline, grasses have returned to ... eye, the marsh in those places seems healthy again, ... service of the marsh coastal protection remains ... ecosystem function hasn,t come back," said ecologist Mark Bertness, ... the study in the journal Biological Conservation . ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Iberian pig genome remains unchanged after 5 centuries 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... in imaging technology using a combination of light and ... details inside the body. Access to this level of ... but it also has the potential to help health ... symptoms arise. Details describing this advance are published online ...
... Mich. Late-preterm babies those born between 34 and ... and emotional problems, regardless of maternal IQ or demographics, according ... the current edition of the journal Pediatrics . ... have been associated with such problems before, the study represents ...
... more than 60 guides and anglers in the Florida Keys ... assisting in the annual bonefish census. This year,s count, held ... 25-percent from an 8-year mean estimate of 316,805 bonefish to ... Jerry Ault, a fisheries scientist with the University of Miami,s ...
Cached Biology News:Medical imaging breakthrough uses light and sound to see microscopic details inside our bodies 2Late-preterm babies at greater risk for problems later in childhood 2Fall bonefish census sounds warning bell that warrants careful future monitoring 2
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
X-Gal...
Recombinant Rat CINC-2 alpha, CF...
RABBIT ANTI SRC-RSV...
Biology Products: